Nuclera and University of Cambridge researchers demonstrate rapid structural analysis of challenging drug target

Nuclera, the biotechnology company enabling access to innovative protein technologies, today announced the publication of research conducted in collaboration with researchers at the University of Cambridge's Department of Biochemistry, demonstrating a rapid, cell-free approach utilizing proprietary nanodisc technology to produce challenging protein drug-targets for high-resolution structural analysis.

The research, published as a preprint on bioRxiv, reports a 3.38 Å resolution cryo-EM structure of an engineered human adenosine A2A receptor (A2AR) complex bound to an antagonist, with the workflow from initial gene assembly to cryo-EM sample preparation completed in four days. The findings demonstrate the potential to overcome a longstanding bottleneck in structural biology, enabling faster access to difficult to express proteins and supporting structure-based drug discovery.

GPCRs are a major class of therapeutic targets. While advances in cryo-EM have enabled increasingly detailed structural analysis, obtaining sufficient quantities of stable, correctly folded GPCRs remains a bottleneck, with conventional production and purification approaches often requiring extensive optimization.

To address this, researchers combined Nuclera's protein discovery system with the University of Cambridge's cryo-EM expertise. Using cell-free protein synthesis, the team screened A2AR constructs against six lipid nanodisc conditions from Nuclera's GPCR nanodisc panel to optimize protein expression. One of the highest-yielding conditions was then scaled up for purification, quality assessment and cryo-EM analysis. The resulting material enabled high-resolution structural analysis of the antagonist-bound A2AR complex, with the receptor architecture closely matching that of a conventionally produced reference.

To investigate the wider applicability of the approach, the researchers also produced and purified a further 12 GPCRs spanning Classes A, B and C, including six orphan receptors, for which endogenous activating ligands have not been identified. These additional proteins were assessed using fluorescence-detection size-exclusion chromatography (FSEC), demonstrating the potential to apply the production workflow across diverse GPCR targets, supporting further structural and biophysical investigations.

Advances in cryo-EM have transformed our ability to investigate protein structures, but obtaining suitable samples remains a major challenge, particularly for complex membrane proteins. This research demonstrates that rapid, cell-free protein production can deliver high-quality, active protein suitable for high-resolution structural analysis, potentially opening up opportunities to investigate a wider range of challenging drug targets."

Dr. Dimitri Chirgadze, Cryo-EM Facility Manager, Department of Biochemistry, University of Cambridge

Dr. Michael Chen, Co-founder and Chief Scientific and Business Officer at Nuclera, commented: "Access to membrane proteins remains a significant obstacle in drug discovery. By combining our cell-free protein synthesis and proprietary nanodisc technology with the University of Cambridge's structural biology expertise, we have demonstrated a faster route to producing proteins suitable for high-resolution analysis. This represents an important step towards making difficult-to-study drug targets more accessible, with the potential to accelerate structural biology research and streamline future drug discovery."

Nuclera will present research relating to the preprint at PEGS Europe, during the session "From Gene to Grid in Four Days: A Cell-Free Route to GPCR Cryo-EM", delivered by Dr Audrey Dubourg, on 19 November 2026 at 12:15pm UTC.

Nuclera will also host a webinar with Dimitri Chirgadze from the University of Cambridge on 15 December 2026, exploring the findings and their implications for GPCR structural biology. Registration is available here: Webinar - Gene to Grid in Four Days: Cell-Free GPCRs for Cryo-EM - Nuclera

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Nuclera. (2026, November 17). Nuclera and University of Cambridge researchers demonstrate rapid structural analysis of challenging drug target. News-Medical. Retrieved on November 17, 2026 from https://www.news-medical.net/news/20261117/Nuclera-and-University-of-Cambridge-researchers-demonstrate-rapid-structural-analysis-of-challenging-drug-target.aspx.

  • MLA

    Nuclera. "Nuclera and University of Cambridge researchers demonstrate rapid structural analysis of challenging drug target". News-Medical. 17 November 2026. <https://www.news-medical.net/news/20261117/Nuclera-and-University-of-Cambridge-researchers-demonstrate-rapid-structural-analysis-of-challenging-drug-target.aspx>.

  • Chicago

    Nuclera. "Nuclera and University of Cambridge researchers demonstrate rapid structural analysis of challenging drug target". News-Medical. https://www.news-medical.net/news/20261117/Nuclera-and-University-of-Cambridge-researchers-demonstrate-rapid-structural-analysis-of-challenging-drug-target.aspx. (accessed November 17, 2026).

  • Harvard

    Nuclera. 2026. Nuclera and University of Cambridge researchers demonstrate rapid structural analysis of challenging drug target. News-Medical, viewed 17 November 2026, https://www.news-medical.net/news/20261117/Nuclera-and-University-of-Cambridge-researchers-demonstrate-rapid-structural-analysis-of-challenging-drug-target.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Comments are closed

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Nuclera appoints Joseph Bertelsen as Chief Commercial Officer